September 20, 2010 - A phase 1 porcine model study demonstrated that it is possible to successfully and repeatedly deliver a mitral valve implant.
CardiAQ Valve Technologies (CVT) will present the results of the study regarding its transcatheter delivery system at the Transcatheter Cardiovascular Therapeutics (TCT) conference on Wednesday, Sept. 22. The company hopes to begin a first-in-man trial in 2011.
"There remains an enormous unmet clinical need for the overwhelming majority of patients who suffer from mitral regurgitation (MR)," said Arshad Quadri, M.D., co-founder, chairman and chief medical officer of CVT. "The fact is that a large majority of these patients suffer from functional MR and are too sick to undergo heart valve surgery. We believe that the applicability and efficacy of current transcatheter repair technologies are limited and that transcatheter mitral valve replacement will provide more effective treatment of MR to a wider range of patients."
For more information: www.cardiaq.com
April 24, 2024 
